QIAGEN Reports Results for Third Quarter and First Nine Months of 2018
-
Q3 2018 results exceed targets as QIAGEN on track to achieve 2018
goals:
- Net sales of $377.9 million +3.8% reported (+6.5% at constant exchange rates, or CER vs. ~6% CER guidance)
- EPS of $0.26; adjusted EPS $0.35 ($0.36 CER vs. ~$0.33-0.34 CER guidance)
- Free cash flow for first nine months of 2018 rises 21% to $176.7 million
-
Sample to Insight portfolio building momentum:
- QuantiFERON latent TB test: Maintains solid double-digit CER growth pace, launch of new automation options provide faster workflows for customers
- QIAstat-Dx: Establishing European footprint in growing market for syndromic testing, on track for U.S. launch in 2019 and menu expansion
- NeuMoDx: New strategic partnership to address large segment of the Molecular Diagnostics market for integrated PCR
- NGS: Launch of universal RNA library preparation products and new oncology panels for GeneReader NGS System
- QIAGEN reaffirms 2018 net sales outlook and raises target for adjusted EPS
VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2018, making progress on goals set for 2018 while driving global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.
Please find the full press release here
View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005755/en/
QIAGEN N.V.
John Gilardi, +49 2103 29 11711 and +1 240 686 2222
Vice
President Corporate Communications and Investor Relations
[email protected]
or
Dr.
Sarah Fakih, +49 2103 29 11457
Director Investor Relations
[email protected]
or
Dr.
Thomas Theuringer, +49 2103 29 11826 and +1 240 686 7425
Senior
Director Public Relations and Digital Communications
[email protected]
Source: QIAGEN N.V.